Mol Cell Biochem 2006, 286: 67–76 PubMedCrossRef 13 Fong WG, Lis

Mol Cell Biochem 2006, 286: 67–76.Saracatinib PubMedCrossRef 13. Fong WG, Liston P, Rajcan-Separovic

E, St Jean M, Craig C, Korneluk RG: Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000, 70: 113–122.PubMedCrossRef 14. Ng KC, Campos EI, Martinka M, Li G: XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 2004, 123: 1127–1134.PubMedCrossRef 15. Lee MG, Huh JS, Chung SK, Lee JH, Byun DS, Ryu BK, Kang MJ, Chae KS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG: Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: PRN1371 in vivo implication for attenuated p53 response to apoptotic stresses. Oncogene 2006, 25: 5807–5822.PubMedCrossRef

16. Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG: Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003, 63: 7068–7075.PubMed 17. Joensuu TK, Nilsson S, Holmberg AR, Marquez M, Tenhunen M, Saarto T, Joensuu H: Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer. Ann N Y Acad Sci 2004, 1028: 361–374.PubMedCrossRef 18. Liu Stattic research buy Y: Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions. Cancer Lett 2006, 239: 21–26.PubMedCrossRef 19. Moller LN, Stidsen CE, Hartmann B, Holst JJ: Somatostatin receptors. Biochim Biophys Acta 2003, 1616: 1–84.PubMedCrossRef 20. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W: Regulation and function of somatostatin receptors. J Neurochem 2004, 89: 1057–1091.PubMedCrossRef 21. Tatoud R, Degeorges A, Prevost G, Hoepffner JL, Gauville C, Millot

G, Thomas F, Calvo Mannose-binding protein-associated serine protease F: Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog. Mol Cell Endocrinol 1995, 113: 195–204.PubMedCrossRef 22. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986, 315: 663–666.PubMedCrossRef 23. Liu Z, Marquez M, Nilsson S, Holmberg AR: Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin. Oncol Rep 2009, 22: 1451–1458.PubMed 24. Liu Z, Marquez M, Nilsson S, Holmberg AR: Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep 2008, 20: 151–154.PubMed 25. Brevini TA, Bianchi R, Motta M: Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J Clin Endocrinol Metab 1993, 77: 626–631.PubMedCrossRef 26.

Related posts:

  1. J Bacteriol

    2006,188(6):2290–2293 PubMedCrossRef 17 Mars
  2. Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base
  3. J Immunol Methods 2005, 298: 61–72 PubMedCrossRef 19 Lin W, Vosk
  4. Periodontol 2006, 42:80–87 CrossRef 8 Zijnge V, Ammann T, Thurnh
  5. Gastroenterology 2005, 128:1229–1242 PubMedCrossRef 11 Torres LE
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>